BG107289A - 3 - азот - 6,7 - дикислородни стероиди и тяхното използване - Google Patents

3 - азот - 6,7 - дикислородни стероиди и тяхното използване Download PDF

Info

Publication number
BG107289A
BG107289A BG107289A BG10728902A BG107289A BG 107289 A BG107289 A BG 107289A BG 107289 A BG107289 A BG 107289A BG 10728902 A BG10728902 A BG 10728902A BG 107289 A BG107289 A BG 107289A
Authority
BG
Bulgaria
Prior art keywords
compound
hydrogen
carbon
substituted
mmol
Prior art date
Application number
BG107289A
Other languages
Bulgarian (bg)
English (en)
Inventor
Jeffery RAYMOND
Claudia KASSERRA
Yaping Shen
Original Assignee
Inflazyme Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inflazyme Pharmaceuticals Limited filed Critical Inflazyme Pharmaceuticals Limited
Publication of BG107289A publication Critical patent/BG107289A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0011—Unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0042—Nitrogen only
    • C07J71/0047—Nitrogen only at position 2(3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0057—Nitrogen and oxygen
    • C07J71/0063—Nitrogen and oxygen at position 2(3)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG107289A 2000-04-28 2002-11-19 3 - азот - 6,7 - дикислородни стероиди и тяхното използване BG107289A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20061700P 2000-04-28 2000-04-28
PCT/CA2001/000581 WO2001083512A1 (fr) 2000-04-28 2001-04-30 Steroides de 3-nitrogene-6,7-dioxygene et utilisations

Publications (1)

Publication Number Publication Date
BG107289A true BG107289A (bg) 2003-07-31

Family

ID=22742458

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107289A BG107289A (bg) 2000-04-28 2002-11-19 3 - азот - 6,7 - дикислородни стероиди и тяхното използване

Country Status (34)

Country Link
US (4) US6635629B2 (fr)
EP (1) EP1278763B1 (fr)
JP (1) JP2003531916A (fr)
KR (1) KR20030045671A (fr)
CN (1) CN1214039C (fr)
AP (1) AP1825A (fr)
AT (1) ATE353909T1 (fr)
AU (2) AU5208401A (fr)
BG (1) BG107289A (fr)
BR (1) BR0110419A (fr)
CA (1) CA2418748A1 (fr)
CO (1) CO5590904A2 (fr)
DE (1) DE60126597T2 (fr)
DK (1) DK1278763T3 (fr)
DZ (1) DZ3355A1 (fr)
EE (1) EE200200613A (fr)
ES (1) ES2282247T3 (fr)
HK (1) HK1050694A1 (fr)
HR (1) HRP20020944A2 (fr)
HU (1) HUP0300908A2 (fr)
IL (2) IL152448A0 (fr)
MA (1) MA25808A1 (fr)
MX (1) MXPA02010645A (fr)
NO (1) NO324873B1 (fr)
NZ (1) NZ522181A (fr)
OA (1) OA12255A (fr)
PL (1) PL365798A1 (fr)
PT (1) PT1278763E (fr)
RU (1) RU2291873C2 (fr)
SK (1) SK15692002A3 (fr)
UA (1) UA79229C2 (fr)
WO (1) WO2001083512A1 (fr)
YU (1) YU88102A (fr)
ZA (1) ZA200208631B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
SK15692002A3 (sk) * 2000-04-28 2003-11-04 Inflazyme Pharmaceuticals Limited 3-Amino-6,7-dioxygénované steroidy a s nimi súvisiace použitie
US20050070487A1 (en) * 2001-04-24 2005-03-31 Nyce Jonathan W. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
CA2447780A1 (fr) 2001-05-22 2002-11-28 Inflazyme Pharmaceuticals Ltd. Ameliorations d'un procede relatif a la chimie des steroides
EP1526140B1 (fr) * 2002-08-01 2008-11-05 Astellas Pharma Inc. Echangeur sodium-calcium dependant du potassium
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20110209699A1 (en) * 2003-07-31 2011-09-01 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
AU2004281998A1 (en) * 2003-10-20 2005-04-28 Inflazyme Pharmaceuticals, Ltd Crystalline forms of 3-beta-amino 17-methylene androstane-6-alpha 7-beta-diol hydrochloride
FR2861077B1 (fr) * 2003-10-20 2006-03-03 Aventis Pharma Sa Formes cristallines du chlorydrate de 3-beta-amino, 17-methylene, androstane-6-alpha, 7-beta-diol
US20080051382A1 (en) * 2003-10-20 2008-02-28 Inflazyme Pharmaceuticals Ltd. Crystalline Forms of 3-Beta-Amino 17-Methylene Androstane-6-Alpha 7-Beta-Diol Hydrochloride
US20090317477A1 (en) * 2004-03-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US20050227927A1 (en) * 2004-03-31 2005-10-13 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
US20050222049A1 (en) * 2004-03-31 2005-10-06 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a glucocorticosteroid for treatment of asthma, chronic obstructive pulmonary disease or allergic rhinitis
AU2008326386B2 (en) * 2007-11-21 2014-07-31 The Procter & Gamble Company Preparations, methods and kits useful for treatment of cough
JP5655243B2 (ja) * 2009-10-19 2015-01-21 国立大学法人 熊本大学 インドキシル硫酸の産生の阻害剤のスクリーニング方法、インドキシル硫酸代謝産生阻害剤、及び腎障害軽減剤
CN103980338B (zh) 2010-01-15 2017-04-26 苏州润新生物科技有限公司 蟾蜍灵衍生物、其药物组合物及用途
NZ605348A (en) 2010-07-09 2015-01-30 Biogen Idec Hemophilia Inc Factor ix polypeptides and methods of use thereof
EP2670763B1 (fr) 2011-02-02 2018-08-01 Suzhou Neupharma Co., Ltd Certaines entités chimiques, compositions et procédés
WO2013165924A1 (fr) 2012-04-29 2013-11-07 Neupharma, Inc. Certaines entités chimiques, compositions et procédés
US20150252345A1 (en) 2012-09-25 2015-09-10 Biogen Idec Ma Inc. Methods of Using FIX Polypeptides
WO2014143561A1 (fr) 2013-03-14 2014-09-18 Aquinox Pharmaceuticals Inc. Modulateurs de ship1 et méthodes associées
KR20220110337A (ko) 2013-03-14 2022-08-05 에퀴녹스 파머수티칼스 (캐나다) 인코포레이티드 Ship1 조절제 및 그와 관련된 방법
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
CN104744547B (zh) * 2013-12-27 2017-02-15 天津医科大学 一种抗乳腺癌转移作用的孕甾烷生物碱衍生物及医药用途
CA2986790A1 (fr) 2015-06-26 2016-12-29 Aquinox Pharmaceuticals (Canada) Inc. Formes solides cristallines du sel d'acetate de (1s,3s,4r)-4-((3as,4r,5s,7as)-4-(aminomethyl)-7a-methyl-1-methyleneoctahydro-1h-inden-5-yl)-3-(hydroxymethyl)-4-methylcyclohexanol
US10053415B2 (en) 2016-01-20 2018-08-21 Aquinox Pharmaceuticals (Canada) Inc. Synthesis of a substituted indene derivative
EP3774836B1 (fr) * 2018-04-06 2023-10-04 Taro Pharmaceuticals Inc. Dérivés d'hexadécahydro-1 h-cyclopenta [a]phénanthrène utiles dans le traitement de la douleur et de l'inflammation
AU2019247513A1 (en) 2018-04-06 2020-10-22 Taro Pharmaceuticals Inc. Indene derivatives useful in treating pain and inflammation
CN112533905A (zh) 2018-04-06 2021-03-19 塔罗制药公司 可用于治疗疼痛和炎症的茚衍生物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3682983A (en) * 1969-11-12 1972-08-08 Klaus Prezewowsky Preparation of {66 {11 {11 -17 ethinyl steroids
AU654474B2 (en) 1990-01-18 1994-11-10 Cura Nominees Pty Ltd Glycoalkaloids
US5877185A (en) 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
CA2086221C (fr) 1992-12-23 2003-07-15 Raymond J. Andersen Contignasterol et 3-alpha-hydroxy-6-alpha hydroxy-7-beta hydroxy-15-keto-14-beta steroides apparentes utilises comme agents anti-inflammatoire et anti-thrombotique
ES2123133T3 (es) 1993-03-10 1999-01-01 Magainin Pharma Derivados esteroidianos, composiciones farmaceuticas que contienen estos derivados esteroidianos y utilizacion de estos ultimos como antibioticos o desinfectantes.
US5817632A (en) * 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5856535A (en) 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
WO1996036230A1 (fr) 1995-05-16 1996-11-21 The Salk Institute For Biological Studies Modulateurs pour de nouveaux membres de la superfamille des recepteurs steroide/thyroide
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5874597A (en) * 1995-06-07 1999-02-23 Magainin Pharmaceuticals, Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US6046185A (en) * 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
US6060465A (en) * 1997-02-06 2000-05-09 Miljkovic; Dusan Bile acids and their derivatives as glycoregulatory agents
CA2322847C (fr) 1998-03-06 2008-05-13 Brigham Young University Derives antibiotiques de steroides
SK15692002A3 (sk) * 2000-04-28 2003-11-04 Inflazyme Pharmaceuticals Limited 3-Amino-6,7-dioxygénované steroidy a s nimi súvisiace použitie

Also Published As

Publication number Publication date
AP1825A (en) 2008-02-03
BR0110419A (pt) 2004-02-25
CO5590904A2 (es) 2005-12-30
DE60126597T2 (de) 2007-10-31
CN1430625A (zh) 2003-07-16
CN1214039C (zh) 2005-08-10
US6635629B2 (en) 2003-10-21
ATE353909T1 (de) 2007-03-15
CA2418748A1 (fr) 2001-11-08
US7112580B2 (en) 2006-09-26
HRP20020944A2 (en) 2004-02-29
SK15692002A3 (sk) 2003-11-04
EP1278763B1 (fr) 2007-02-14
MA25808A1 (fr) 2003-07-01
ES2282247T3 (es) 2007-10-16
DE60126597D1 (de) 2007-03-29
EE200200613A (et) 2004-04-15
NO20025106D0 (no) 2002-10-24
US20050215534A9 (en) 2005-09-29
AP2002002659A0 (en) 2002-12-31
KR20030045671A (ko) 2003-06-11
JP2003531916A (ja) 2003-10-28
IL152448A0 (en) 2003-05-29
HUP0300908A2 (hu) 2003-07-28
PL365798A1 (en) 2005-01-10
WO2001083512A1 (fr) 2001-11-08
HK1050694A1 (en) 2003-07-04
US20040034216A1 (en) 2004-02-19
PT1278763E (pt) 2007-05-31
ZA200208631B (en) 2004-02-23
YU88102A (sh) 2006-01-16
NO324873B1 (no) 2007-12-17
UA79229C2 (en) 2007-06-11
AU2001252084B2 (en) 2006-07-06
DK1278763T3 (da) 2007-06-11
IL152448A (en) 2006-12-31
US20020072510A1 (en) 2002-06-13
EP1278763A1 (fr) 2003-01-29
US20070060553A1 (en) 2007-03-15
AU5208401A (en) 2001-11-12
NZ522181A (en) 2005-04-29
NO20025106L (no) 2002-12-18
US20040138186A1 (en) 2004-07-15
RU2291873C2 (ru) 2007-01-20
MXPA02010645A (es) 2004-04-20
OA12255A (en) 2006-05-11
DZ3355A1 (fr) 2001-11-08

Similar Documents

Publication Publication Date Title
BG107289A (bg) 3 - азот - 6,7 - дикислородни стероиди и тяхното използване
KR100394548B1 (ko) Gaba수용체의알로스테릭조절을위한안드로스탄및프레그난계열화합물
JP6130087B1 (ja) １７−ヒドロキシ−１７−ペンタフルオロエチル−エストラ−４，９（１０）−ジエン−１１−アリール誘導体、その製造方法、その誘導体を利用した諸疾患の治療
AU780989B2 (en) 3alpha-hydroxy-3beta methoxymethyl-21-heterocycle substituted steroids with anesthetic activity
JP3333210B2 (ja) 新規プレドニソロン誘導体および該化合物を含有する薬剤
AU2001252084A1 (en) 3-nitrogen-6,7-dioxygen steroids and uses related thereto
JPH06501962A (ja) アンドロスタン及びプレグナン系列の構成要素によるｇａｂａ受容体のアロステリック修飾のための方法、組成物及び化合物
JP2000501732A (ja) 抗炎症薬として有用な新規ステロイドナイトライト／ナイトレートエステル誘導体
JP5809172B2 (ja) プロゲステロン受容体アンタゴニスト
CA2768453A1 (fr) Derives 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-acyloxyalcenylphenyle, procedes de preparation et utilisation pour le traitement de maladies
DE69417248T2 (de) Delta 16 ungesättigtes c17 heterocyclische steroide zur verwendung als steroid c17-20 lyase inhibitoren
JP3913475B2 (ja) ステロイドスルファターゼ阻害剤並びに該阻害剤の製造及び使用方法
KR960002913B1 (ko) 아미노알킬 측쇄를 갖는 사이클릭 탄화수소
NO168892B (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 17beta-(cyclopropyloxy)androst-5-en-3beta-ol-derivater
JPH09291086A (ja) 心血管系に活性な新規ｓｅｃｏ−Ｄステロイド類および同ステロイドを含有する医薬組成物
EP3937923B1 (fr) Rétinoïdes synthétiques destinés à être utilisés dans l'activation de rar
JP4768181B2 (ja) １１β−アリール−１７，１７−スピロチオラン置換ステロイド
DE19961219A1 (de) 11beta-Phenylestratrien-Derivate mit Fluoralkylgruppen in der aromatischen Seitenkette, deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
KR102534043B1 (ko) Cns 장애의 치료에서 사용하기 위한 3.알파.-에타인일, 3.베타.-하이드록시-5.알파.-프레그난-20-옥심
JPH0912593A (ja) 心臓血管系に活性な新規１７−ヒドロキシイミノアルキルおよび１７−ヒドロキシイミノメチルアルケニルシクロペンタンペルヒドロフェナントレン誘導体、それらの製造方法およびそれらの化合物を含む医薬組成物